SCHEMBL4353891

SCHEMBL4353891

CC(=O)c1cc(Cl)cc(NCc2ccccc2Sc2ccc(Cl)c(Cl)c2)c1O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.39
PTGS1 P23219 1/20 0.35
TBXAS1 P24557 1/20 0.35
MAPK1 P28482 1/20 0.35
PTGS2 P35354 1/20 0.35
MAPK14 Q16539 1/20 0.35
SLC6A4 P31645 2/20 0.34
SLC6A2 P23975 1/20 0.34
SLC6A3 Q01959 1/20 0.34
HTR1A P08908 1/20 0.34
HTR3A P46098 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
PTPRG P23470 2/20 0.34
ALDH1A1 P00352 2/20 0.34
LMNA P02545 2/20 0.34
BLM P54132 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
NOD2 Q9HC29 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6671731 0.92 SLC6A2 (0.40) SMN1; SMN2SLC6A4SLC6A2SLC6A3ALDH1A1
SCHEMBL4351160 0.91 SLC6A4 (0.43) SMN1; SMN2MAPK1SLC6A4CYP2D6CYP2C9
SCHEMBL4349809 0.89 SMN1; SMN2 (0.43) SMN1; SMN2MAPK1SLC6A4SLC6A2SLC6A3
SCHEMBL4354316 0.89 BLM (0.38) SMN1; SMN2MAPK1SLC6A4SLC6A2SLC6A3
SCHEMBL4354650 0.89 SLC6A2 (0.47) SMN1; SMN2MAPK1SLC6A4SLC6A2SLC6A3
SCHEMBL4343735 0.87 ITGB2 (0.39) SMN1; SMN2MAPK1ALDH1A1LMNACXCR2
SCHEMBL4351799 0.86 LMNA (0.40) SMN1; SMN2ALDH1A1LMNABLMNPSR1
SCHEMBL4360001 0.86 POLB (0.50) SMN1; SMN2CYP2C9CYP2C19ALDH1A1LMNA
SCHEMBL4357669 0.86 GAA (0.40) SMN1; SMN2TBXAS1MAPK1MAPK14SLC6A4
SCHEMBL6671733 0.85 SLC6A2 (0.35) SMN1; SMN2SLC6A4SLC6A2SLC6A3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
EP-1539683-A2 PHENOL DERIVATIVES AND THEIR USE AS ROTAMASE INHIBITORS Jerini AG (DE) 2005-06-15 EP claimed
WO-2004026815-A2 PHENOL DERIVATIVES AND THEIR USE AS ROTAMASE INHIBITORS JERINI AG (DE) 2004-04-01 WO claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 SMN1; SMN2 1791/4885PTGS1 2026/4885TBXAS1 2592/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 SMN1; SMN2 3250/4885PTGS1 1789/4885TBXAS1 2599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.